Cardiovascular Market 2012 Deals & 2013 CV Disease Drug Advances Discussed in New Research at

Share Article

Research reports ‘The Silent Killer: Recent Advances in Cardiovascular Disease’ and 'Cardiovascular Partnering Yearbook 2013' are now available at

Not only is cardiovascular disease a “Silent Killer”, it is also a commercial time bomb where the risk/reward ratio for any company willing to participate needs to be carefully considered.

The research on recent advances in Cardiovascular diseases report provides you with a systematic appraisal into the current and future CV market, including: a detailed review of the leading brands and how they are being positioned in the market, in addition to the potential impact of generics, assessment of key products in development, identifying ‘Ones to Watch’ in late-stage clinical development where proof of concept data has been established, review of products that are ‘Waiting in the Wings’ in early-stage clinical development where Point-of-Care data is being gathered, analysis of the potential of ‘Long Shots’ which represent new and innovative products where the scientific rationale has yet to be fully tested and antilipidemics. Read more @

The Cardiovascular Partnering Yearbook 2013 report provides comprehensive understanding and unprecedented access to the partnering deals and agreements entered into by the world’s leading healthcare companies during 2012. Using this report, dealmakers will effectively and efficiently gain insight into the partnering activities of the past year. The report allows you to view all the partnering and alliances deals announced worldwide. Partnering deals in this research are listed by: Company A-Z, Headline value, Stage of development at signing, Deal component type, Therapy area and Technology type. Each deal title links via weblink to an online version of the deal record at Current Agreements and where available, the contract document, providing easy access to each contract document on demand. Read more @

There are nearly 300 medicines in clinical development to treat cardiovascular disease. Successful players will, necessarily, need to cannibalise their existing cardiovascular franchises in order to limit the impact of generic erosion when their patents expire, whilst at the same time investing in alternative therapies with better, more efficacious outcomes. This is a significant challenge given the high barrier to entry and unmet clinical needs. Not only is cardiovascular disease a “Silent Killer”, it is also a commercial time bomb where the risk/reward ratio for any company willing to participate needs to be carefully considered.

Few questions these reports will you help answer include:

  • Will AstraZeneca’s Crestor win its fight for supremacy before generic rosuvastatin reaches the market?
  • Kynamro approved in the US but not in Europe… what next?
  • What new products are in development from BMS/Simcere; Dr Reddy and DezimaPharma?
  • Boehringer Ingelheim’s Pradaxa is first to the market but what safety issues have been flagged up?
  • Why has GlaxoSmithKline's Arixtra failed to impress?
  • Why have Diovan generics been slow off the mark and have pill combinations offered any protection?
  • Will Takeda’s Edarbi become the new gold standard in a market dominated by generics?
  • Why has Tekturna not lived up to its promise, do direct renin inhibitors have a future?
  • and more...

Get in-depth understanding of recent dealmaking trends during 2012, comprehensive access to all deals entered into by the world’s biopharma companies during 2012, detailed access to actual partnership deals and contracts entered into by the leading fifty bigpharma companies, understand the key deal terms companies have agreed in previous deals and undertake due diligence to assess suitability of your proposed deal terms for partner companies with the help of data, information and analysis in these reports.

We have the latest collection of Pharmaceutical reports ( by leading industry experts from around the world to help you in your market research and business intelligence process. You may want to explore the Disease and Therapy Review reports we offer @ as well as few country focused wound care market research reports @

About Us: is an online library of market research reports offering 3,50,000+ syndicated reports ( ) on more than 500 micro segments by leading market research publishers from across the globe. We also offer company profiles and SWOT analysis reports for organizations in multiple industries. Our sales and research experts offer 24 X 7 support to our customers through phone and email communication. Feel free to write to us with any specific requirements you may have on your business intelligence needs.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Priyank Tiwari
Market Reports Online
+1 (888) 391-5441
Email >
Market Reports Online
since: 09/2012
Like >
Visit website